Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Targeting Glutamine Dependence through GLS1 Inhibition Suppress Multiple Myeloma and Phenomenon of Sars-Cov-2 Infectious Disease

Seiichi Okabe, Yuko Tanaka, Akihiko Gotoh

Blood (2023) 142 (Supplement 1): 6585.

https://doi.org/10.1182/blood-2023-188693

Published: 2023

Journal Articles

The Pivotal Role of Glutaminolysis in Multiple Myeloma: Novel Strategies for Target Therapies Against Myeloma

Seiichi Okabe, Yuko Tanaka, Akihiko Gotoh

Blood (2021) 138 (Supplement 1): 4707.

https://doi.org/10.1182/blood-2021-152134

Published: 2021

Journal Articles

The Pivotal Role of Nicotinamide Phosphoribosyl Transferase in Chronic Myeloid Leukemia Cells Under Hypoxic Condition

Seiichi Okabe, Yuko Tanaka, MD PhD, Akihiko Gotoh, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-140202

Published: 2020

Journal Articles

Targeting Glycolysis in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant in Hypoxic Conditions

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD

Blood (2019) 134 (Supplement_1): 4344.

https://doi.org/10.1182/blood-2019-129818

Published: 2019

Journal Articles

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD

Blood (2019) 134 (Supplement_1): 5369.

https://doi.org/10.1182/blood-2019-129768

Published: 2019

Journal Articles

Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2018-99-114030

Published: 2018

Journal Articles

Targeting Insulin-like Growth Factor in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant Cells

Yuko Tanaka, Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yoshikazu Ito, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 5155.

https://doi.org/10.1182/blood-2018-99-114750

Published: 2018

Journal Articles

Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)

Tetsuzo Tauchi, MD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 1249.

https://doi.org/10.1182/blood.V130.Suppl_1.1249.1249

Published: 2017

Journal Articles

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 3828.

https://doi.org/10.1182/blood.V130.Suppl_1.3828.3828

Published: 2017

Journal Articles

ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study

Tetsuzo Tauchi, MD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 1582.

https://doi.org/10.1182/blood.V130.Suppl_1.1582.1582

Published: 2017

Journal Articles

Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 5241.

https://doi.org/10.1182/blood.V130.Suppl_1.5241.5241

Published: 2017

Journal Articles

Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC)

Tetsuzo Tauchi, MDPhD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MDPhD, Kazuma Ohyashiki, MD PhD

Blood (2016) 128 (22): 3150.

https://doi.org/10.1182/blood.V128.22.3150.3150

Published: 2016

Journal Articles

Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL

Meixian Huang, MD, Takeshi Inukai, MD, PhD, Keiko Kagami, BD, Masako Abe, BD, Tamao Shinohara, MD, Atsushi Watanabe, MD PhD, Koshi Akahane, MD PhD, Shinpei Somazu, MD, Hiroko Oshiro, MD PhD, Kumiko Goi, MD PhD, Yasuhiro Maeda, MD PhD, Seiichi Okabe, MD PhD, Shinya Kimura, MD, PhD, Kanji Sugita, MD, PhD

Blood (2016) 128 (22): 1059.

https://doi.org/10.1182/blood.V128.22.1059.1059

Published: 2016

Journal Articles

Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2016) 128 (22): 5428.

https://doi.org/10.1182/blood.V128.22.5428.5428

Published: 2016

Journal Articles

Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL Point Mutation

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MDPhD, Yuko Tanaka, MDPhD, Juri Sakuta, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2015) 126 (23): 2769.

https://doi.org/10.1182/blood.V126.23.2769.2769

Published: 2015

Journal Articles

Dual HDAC and PI3K Inhibitor, CUDC-907 Alone or in Combination with ABL Tyrosine Kinase Inhibitor Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MDPhD, Yuko Tanaka, MDPhD, Juri Sakuta, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2015) 126 (23): 3693.

https://doi.org/10.1182/blood.V126.23.3693.3693

Published: 2015

Journal Articles

Targeting the Hedgehog Signaling Pathway By PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms

Tetsuzo Tauchi, MDPhD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MDPhD, Kaoru Tohyama, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2015) 126 (23): 791.

https://doi.org/10.1182/blood.V126.23.791.791

Published: 2015

Journal Articles

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, MD PhD, Seiichiro Katagiri, MD, Seiichi Okabe, MD PhD, Yuko Tanaka, MDPhD, Kazuma Ohyashiki, MD, PhD

Blood (2014) 124 (21): 905.

https://doi.org/10.1182/blood.V124.21.905.905

Published: 2014

Journal Articles

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, MDPhD, Seiichiro Katagiri, MD PhD, Kazuma Ohyashiki

Blood (2014) 124 (21): 3127.

https://doi.org/10.1182/blood.V124.21.3127.3127

Published: 2014

Journal Articles

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Seiichiro Katagiri, MD PhD, Tetsuzo Tauchi, MD PhD, Yuu Saito, MD, Tamiko Sugro, MD, Michiyo Asano, MD, Seiichiro Yoshizawa, MD PhD, Juri Sakuta, MD PhD, Daigo Akahane, MD PhD, Yuko Tanaka, MD PhD, Nahoko Furuya, MD PhD, Keiko Ando, MD PhD, Hiroaki Fujimoto, MD, Seiichi Okabe, MD PhD, Moritaka Gotoh, MD PhD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2014) 124 (21): 1797.

https://doi.org/10.1182/blood.V124.21.1797.1797

Published: 2014

NARROW

Targeting Glutamine Dependence through GLS1 Inhibition Suppress Multiple Myeloma and Phenomenon of Sars-Cov-2 Infectious Disease

The Pivotal Role of Glutaminolysis in Multiple Myeloma: Novel Strategies for Target Therapies Against Myeloma

The Pivotal Role of Nicotinamide Phosphoribosyl Transferase in Chronic Myeloid Leukemia Cells Under Hypoxic Condition

Targeting Glycolysis in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant in Hypoxic Conditions

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Targeting Insulin-like Growth Factor in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant Cells

Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study

Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells

Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC)

Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL

Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells

Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL Point Mutation

Dual HDAC and PI3K Inhibitor, CUDC-907 Alone or in Combination with ABL Tyrosine Kinase Inhibitor Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells

Targeting the Hedgehog Signaling Pathway By PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only